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Ulinastatin (UTI), a trypsin inhibitor, is isolated and purified from human urine and has been shown to exert protective effect
on myocardial ischemia reperfusion injury in patients. The present study was aimed at investigating the effect of ulinastatin on
neurologic functions after spinal cord ischemia reperfusion injury and the underlying mechanism. The spinal cord IR model was
achieved by occluding the aorta just caudal to the left renal artery with a bulldog clamp.The drugs were administered immediately
after the clamp was removed. The animals were terminated 48 hours after reperfusion. Neuronal function was evaluated with




were harvested for pathological and biochemical analysis.
Ulinastatin administration significantly improved postischemic neurologic function with concomitant reduction of apoptotic cell
death. In addition, ulinastatin treatment increased SOD activity and decreased MDA content in the spinal cord tissue. Also,
ulinastatin treatment suppressed the protein expressions of Bax and caspase-3 but enhanced Bcl-2 protein expression. These
results suggest that ulinastatin significantly attenuates spinal cord ischemia-reperfusion injury and improves postischemic neuronal
function and that this protection might be attributable to its antioxidant and antiapoptotic properties.
1. Introduction
Spinal cord injury is mainly divided into primary and
secondary injuries according to pathophysiologic features.
Primary injury mainly includes direct injury and ischemic
injury, and it often occurs in a relatively short time after injury
(generally after 4 hours of injury), with the irreversible nerve
damage [1]. The secondary injury often takes place in the
process of perfusion after spinal cord ischemia, causing spinal
cord ischemia-reperfusion injury (SCIRI) which aggravates
the neurofunctional damages of limbs. Spinal cord ischemia-
reperfusion injury remains to be a devastating complication
of thoracic aortic intervention, which may cause delayed
paraplegia [2, 3]. The reasons for SCIRI were generally
considered to be attributable to oxygen free radical-induced
lipid peroxidation, leukocyte activation, inflammatory and
neuronal apoptosis, and so on. Although technological
advancements in surgery, such as hypothermic circulatory
arrest, left heart bypass, intercostal artery reimplantation,
and lumbar drains, have partly reduced complications of
spinal cord injury, the incidence of paraplegia (immediate
and delayed combined) after thoracic aortic intervention still
ranges between 4% and 11% [4, 5]. Unfortunately, a reliable
preventive method has not proven clinically efficacious in
attenuating this injury until now.Themechanisms associated
with delayed paraplegia are still not fully defined. Existing
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studies indicated that the apoptosis of motor neurons may
cause the delayed paraplegia [6], and other studies showed
that the cytokine interleukin- (IL-) 17 may play an important
role in promoting spinal cord neuroinflammation after SCI
via activation of STAT3 [7]. Therefore, it is necessary to
formulate treatment tragedy for inhibiting themotor neurons
apoptosis.
The urinary trypsin inhibitor, also called ulinastatin, is a
protease inhibitor that is purified from human urine with a
molecular weight of 67 kDa and it has been shown to have
anti-inflammatory effect by suppressing the production of
proinflammatory cytokines [8–10] and attenuated postoper-
ative clinical outcome after myocardial ischemia-reperfusion
in patients [11]. Ulinastatin significantly reduced pulmonary
vascular permeability index (PVPI) and extravascular lung
water index (ELWI) through inhibition of lipid peroxidation
[12]. Experimental studies have shown organ protective effect
of ulinastatin on ischemia-reperfusion injury of the lung,
liver, heart, and kidney [13–16]. Ulinastatin also attenuates
focal ischemia-reperfusion injury in rat brain, decreasing
neutrophil infiltration in the ischemic hemisphere [17]. To the
best of our knowledge, it is unknown whether ulinastatin has
neuroprotective effects on spinal cord ischemia-reperfusion
injury.
The aim of this study was to investigate the potential
protective effects of ulinastatin on spinal cord ischemia-
reperfusion injury and to explore its mechanism in relation
to inhibiting neuron apoptosis in a rabbit model.
2. Materials and Methods
2.1. Animals. Adult male New Zealand White rabbits weigh-
ing 2.5–3.0 kg were provided by the Laboratory Animal
Center of Southern Medical University (Guangzhou, China).
Animals were housed at 22–25∘C with a 12 h light/dark
cycle before and after surgery. Standard animal chow and
water were freely accessible. All experimental protocols
were approved by the Institutional Animal Care and Use
Committee of SouthernMedical University and performed in
accordancewith theNational Institutes ofHealth (NIH,USA)
guidelines for the use of experimental animals. The rabbits
were randomized and blindly assigned to three groups, with
eight rabbits per group.
2.2. Experimental Grouping. The groups were as follows.
Sham control group (Sham, 𝑛 = 8): rabbits underwent
laminectomy and abdominal aorta was exposed but with no
aortic occlusion clamp.
Ischemia-reperfusion (IR) group (IR, 𝑛 = 8): rabbits
underwent transient global spinal cord ischemia; the saline
(0.9% NaCl, 5mL/kg) was injected intravenously immedi-
ately after the occlusion clamp was removed.
Ulinastatin group (IR + UTI, 𝑛 = 8): as for ischemia
group, but ulinastatin at the dose of 50,000U/kg (diluted
with saline (0.9% NaCl) to 5mL per kilogram) was injected
intravenously immediately after the occlusion clamp was
removed.
2.3. Experimental Protocols. Anesthesia was induced by
intraperitoneal administration of 30mg/kg ketamine. When
necessary, additional dose of ketamine was administrated. A
22G catheter was inserted into ear artery for measuring the
arterial pressure. An ear vein catheter was placed for admin-
istration of additional medications and fluids. The anesthesia
was maintained by intermittent intravenous injection of
ketamine. The lactated Ringer’s solution (10mL/kg/h) was
intravenously infused. The animals were intubated, placed
supine on a heated operating table, and ventilated with 90%
oxygen. Core body temperature was maintained at 36 ±
0.5∘C. Animals were placed in the supine position for the
surgery. After sterile preparation, a 10 cm midline incision
was made, and the abdominal aorta was exposed through a
transperitoneal approach. Heparin (130U/kg) was adminis-
tered intravenously 5min before clamping for anticoagula-
tion. Approximately 1 cm below the left renal artery, the aorta
was clamped using a bulldog clamp. Ischemia-reperfusion
injury was achieved via occlusion of the abdominal aorta for
40min, and then the clamp was removed. After the surgical
and ischemic interventions, the surgical wound was closed in
layers with 3-0 silk sutures.The animals were given free access
to water and food at room temperature.
At 48 hours after reperfusion, the animals were euth-
anized under deep anesthesia and transcardiac perfusion
with 500mL ice-cold saline was performed. The lumbar
spinal cord (L
3–5 segments) of all animals was removed.
Spinal cord samples were carefully dissected and divided
into two sections. One of the sections was placed in 4%
paraformaldehyde for 24 hours. Following fixation, tissue
sample was embedded in paraffin. The other part of tissue
samplewas flash frozen in liquid nitrogen and stored at−80∘C
until further analysis.
2.4. Functional Assessment. Neurologic function was scored
at 4, 12, 24, and 48 hours after reperfusion by assessing hind-
limb neurologic function using the Tarlov Scoring System.
A score of 0 to 4 was assigned to each animal as follows: 0
= spastic paraplegia and no movement of the lower limbs,
1 = spastic paraplegia and slight movement of the lower
limbs, 2 = good movement of the lower limbs but unable to
stand, 3 = able to stand but unable to walk normally, and 4
= complete recovery and normal gait-hopping. Neurologic
function evaluation was performed by a medical doctor who
was blinded to the experimental groups.
2.5. Assay of SOD and MDA Activities. For biochemical
analysis, spinal cord tissues were washed two times with
cold saline solution and stored in −80∘C until analysis.
Tissue malondialdehyde (MDA) levels were determined as
described [18]. Briefly, MDA was reacted with thiobarbituric
acid by incubating for 1 hour at 95–100∘C and fluorescence
intensity was measured in the n-butanol phase with a
fluorescence spectrophotometry (Hitachi, Mode l F-4010,
Japan), by comparing with a standard solution of 1,1,3,3-
tetramethoxypropane. The results were expressed in terms
of nmol/g wet tissue. Total (Cu–Zn and Mn) superoxide
Oxidative Medicine and Cellular Longevity 3
dismutase (SOD) activity was measured according to reduc-
tion of nitro-blue tetrazolium by xanthine-xanthine oxidase
system as described previously. Enzyme activity leading to
50% inhibition was regarded as one unit. The results were
expressed as U/mg of protein. Protein concentrations were
determined according to Lowry’s method [19].
2.6. Determination of the Expression of Bcl-2, Bax, and
Caspase-3 by Immunohistochemistry. The spinal cord tissue
sections were deparaffinized in xylene and immersed in
graded ethanol and distilled water. Immunohistochemical
staining was performed using the avidin-biotin peroxidase
complex (ABC) method according to the manufacturer’s
instructions (Dako, Carpinteria, CA,USA).The sectionswere
incubatedwith amousemonoclonal anti-Bax IgG2b antibody
(1 : 500, sc-7480, Santa Cruz Biotechnology, CA, USA), a
mouse monoclonal anti-Bcl-2 IgG1 antibody (1 : 20, sc-8392,
Santa Cruz Biotechnology, CA, USA), and caspase-3 (1 : 500,
Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA). The
primary antibody was omitted as a negative control for the
immunostaining. An image of each section was captured
using a light microscope (Canon, Tokyo, Japan) at ×400
magnification and the integrated optical density (IOD) of the
positively stained tissue in each image was determined using
Image Pro Plus software, version 6.0 (Media Cybernetics,
Silver Spring, MD, USA).
2.7. Determination of the Expression of Bcl-2, Bax, and
Caspase-3 Protein by Western Blot. Frozen spinal cord
samples were processed for protein assays using standard
Western blotting analysis as described [20, 21]. In brief,
the samples were homogenized in 5 v of buffer containing
buffer containing sucrose 300mM, HEPES 4mM, EGTA
2mM, phenylmethylsulphonyl fluoride (PMSF) 1mM, and
leupeptin 20mM using a polytron homogenizer at the
maximum speed in five 5 s bursts. The homogenates were
incubated at 4∘C for 30min and then centrifuged at 10,000×g
for 30min at 4∘C. The lysates were collected and the protein
concentration was determined using the BCA Protein Assay
kit. Equal amounts of proteins were separated by SDS-
PAGE and transferred to polyvinylidene difluoride mem-
branes (GE Healthcare Biosciences). The blots were initially
blocked overnight with 5% milk in buffer containing Tris-
HCl 20mM (pH 7.4), NaCl 137mM, 0.05% Tween-20, and
then incubated for 1 hwith anti-Bcl-2 antibody (1 : 1000), anti-
Bax antibody (1 : 1000), anti-caspase-3 antibody (1 : 1000), all
from Santa Cruz Biotechnology, CA, USA. After washing,
the blots were incubated for 1 h at room temperature with
a peroxidase-linked, goat anti-mouse secondary antibody
(1 : 1000 dilution). The internal control was monoclonal anti-
actin antibody (Sigma, St. Louis, USA) diluted 1 : 250. The
bound antibody was then visualized using an enhanced
chemiluminescence (ELC) kit (Amersham). Bcl-2, Bax, and
caspase-3 were quantified densitometrically using suitable
autoradiographs sucrose 300mM, HEPES 4mM, EGTA.
Immunoblot results were quantified with Gel-Pro Analyzer
4.0 software (Media Cybernetics, Silver Spring, MD, USA).
2.8. Terminal Deoxynucleotidyl Transferase-Mediated dUTP-
Biotin Nick End Labeling (TUNEL) Assay. Fixed spinal
cord slices were embedded in paraffin, and 4mm thick
sections were deparaffinized by washing in 100% xylene
and a descending ethanol series (from 100% ethanol two
times to 80% ethanol once and 60% ethanol once). The
sections were stained with haematoxylin and processed as
described [22]. DNA fragments were determined using an
ApopTag in situ apoptosis detection kit (ApopTag, Oncor,
USA). The DNA nick was labelled according to the manu-
facturer’s instructions. Following TUNEL, the sections were
counterstained with haematoxylin. Neurons in which the
nucleus was obviously labeled with diaminobenzidine were
defined as TUNEL-positive. The apoptotic index (AI) was
used to quantify the number of TUNEL positive cells. Five
nonadjacent fields in each section were randomly chosen to
count the total number of neurons and positive cells. The
AI was calculated as follows: AI = (number of apoptotic
cells/total number counted) × 100%.
2.9. Statistical Analysis. All data are expressed as the mean ±
standard deviation (SD). Parametric statistics analyses were
performed by ANOVA followed byDennett’s test formultiple
comparisons or by Student’s 𝑡-test. Nonparametric statistics
analyses were performed by Kruskal-Wallis test followed by
the Mann-Whitney 𝑈 test with Bonferroni correction. 𝑃
values less than 0.05 were considered significant. Statistical
analysis was performed using the Statistical Package for the
Social Sciences version 13.0 program (SPSS, Chicago, IL,
USA).
3. Results
3.1. Neurologic Function. Hind-limb function was recorded
using the Tarlov Scoring System (Figure 1). In the Sham
group, the scores from 4 to 48 h after reperfusion did not
significantly change (𝑃 > 0.05), but in the UTI + IR group
the scores were higher at 24 h and 48 h time points than at 4 h
and 12 h time points (𝑃 < 0.05). The score in the IR group
was higher 4 h after reperfusion than 12 to 48 h (𝑃 < 0.05). At
24 h and 48 h time points, the hind-limb function of UTI + IR
group animals was improved compared to that of IR group
animals (𝑃 < 0.01), but it did not reach the level of Sham
group (𝑃 < 0.05).
3.2. Effect of Ulinastatin on MDA, SOD Levels. To determine
the local oxidative/antioxidative levels, we detected theMDA
content and SOD activities in spinal cord tissue. Spinal
cord IR was associated with significant elevation in MDA
production with concomitant reduction in SOD activity.
Following ischemia-reperfusion injury, the SOD activity in
theUTI+ IR groupwas significantly higher than that in the IR
group, but MDA content in spinal cord tissue was decreased
significantly compared with IR group (Figure 2).
3.3. Immunohistochemistry of Bcl-2, Bax, and Caspase-
3 Proteins. As shown in Figure 3, spinal cord ischemia-
reperfusion resulted in significant increase of Bax and

























Figure 1: Hind-limb function indicated a progressive decline in
function of ischemia-reperfusion IR controls. The scores of Sham
group at the same time point were higher than UTI + IR and
IR groups (∗𝑃 < 0.05). The scores of hind-limb function in IR
group declined from 4 h to 48 h, but rabbits treated with UTI
(UTI + IR group) did not decline; their function stabilized and was
significantly greater (#𝑃 < 0.01) than that in the IR controls at 24 h
and 48 h after reperfusion. In UTI + IR group, function score was
higher at 24 h and 48 h time points than at 4 h and 12 h time points
(⧫𝑃 < 0.05), but the score of IR group was higher at 4 h time point
than at the other time points (⧫𝑃 < 0.05). Values are the means ±
SD, 𝑛 = 8 per group.
caspase-3 protein expression and decrease of Bcl-2 protein
expression as compared with the Sham group.The number of
the positive cells containing Bcl-2 protein expression (brown
stain) increased in the UTI + IR group compared to the IR
control group. The number of positive cells containing Bax
and caspase-3 protein expression (brown stain) decreased in
the UTI + IR group compared with the IR group.
3.4. Western Blot Analysis of Bcl-2, Bax, and Caspase-3
Proteins. The expression of Bax protein was significantly
upregulated in the IR control group as compared to the
Sham group. However, this upregulation of the expression
of Bax protein was significantly inhibited in the IR + UTI
group. With respect to Bcl-2, the expression level in the IR
+ UTI group significantly increased as compared with the
Sham group and the IR group, respectively. The expression
of caspase-3 decreased in the IR + UTI group, but increased
in the IR control group (Figure 4).
3.5. Apoptotic Cell Death Assessed by TUNEL Staining.
TUNEL-positive cells wereminimally detectable in the Sham
group, whereas the IR group showed a significant number of
TUNEL-positive cells. Ulinastatin intervention significantly
decreased the number of TUNEL-positive cells compared to
the IR group (𝑃 < 0.05, Figure 5).
4. Discussion
The aim of this study was to investigate the potential
protective effects of ulinastatin on spinal cord ischemia-
reperfusion injury and to explore the underlying mecha-
nisms. The present study showed that ulinastatin improved
the neurological outcome and reduced the postischemic
apoptotic cell death in neurons by way of decreasing the
levels of MDA, increasing SOD activities, suppressing the
upregulation of the proapoptotic protein expression and the
downregulation of antiapoptotic protein expression.
Spinal cord ischemia and reperfusion injury is a common
postoperative complication following surgeries implicating
the descending and thoracoabdominal aorta, whichmay lead
to catastrophic consequences, such as paraplegia. Spinal cord
ischemia due to hypoperfusion during aortic cross clamping
is largely responsible for spinal cord injury. This injury is
followed by a secondary injury caused by blood reperfu-
sion [23]. The lack of the nutrients and oxygen activates
devastating biochemical cascades, which causes spinal cord
ischemia and reperfusion injury, namely, primary injury
[24]. The primary injury followed by blood reperfusion may
cause additional spinal cord damage, which impairs neuron
function and generates the secondary damage. Secondary
damage to the spinal cord is primarily responsible for
many negative effects of the spinal cord injury (SCI) and
most researches however have focused on understanding the
pathophysiology of the secondary damage and reducing the
amount of delayed cell loss following SCI [25, 26]. It has
been reported that production of reactive oxygen species
(ROS) is a well characterized pathological process during the
reperfusion [27]. The event triggers accumulation of intra-
cellular calcium levels, mitochondrial dysfunction [23]. ROS
causes lipid peroxidation as well as oxidative and nitrative
damage to proteins and nucleic acids [28, 29]. The central
nervous system is primarily composed of lipids, whichmakes
it easily damaged by free-radical-induced lipid peroxidation
[30]. Lipid peroxidation is believed to be one of the primary
pathophysiological mechanisms, which is also implicated in
secondary damage [31]. Under the normal conditions, there
is a balance between the production of ROS and the defense
system, the antioxidants. Once the production of ROS is
beyond the capacity of those antioxidant enzymes (such as
SOD) as happened during reperfusion, oxidative damage
occurred.
Ulinastatin, a protease inhibitor, was a glycoprotein,
which was obtained from human urine with a molecular
weight of 67 kDa [32], and it has been showed to reduce lipid
peroxidation in various models of ischemia-reperfusion or
sepsis [33]. In the present study, ulinastatin treatment atten-
uated lipid peroxidation by decreasing MDA content and
elevating SOD activity in the spinal cord tissue, suggesting
that ulinastatin can attenuate oxidative stress of the spinal
cord tissue. Ulinastatin produced dose-dependent attenua-
tion of the systemic inflammatory response of rats following
lung I/R injury [34], and the doses of ulinastatin had been
used from 5000U/kg to 300000U/kg [17, 34]. Therefore,
we chose 50000U/kg as the treatment dose, and our data
further confirm that ulinastatin inhibits free radicals induced
































Figure 2: (a) SOD activities and MDA levels in rabbit spinal cord. ∗Compared with IR group (𝑃 < 0.01). #Compared with Sham group
(𝑃 < 0.01). Values are the means ± SD, 𝑛 = 8 per group.



































Figure 3:The expression of Bax, Bcl-2, and caspase-3 detected by immunohistochemistry. IR injury promoted Bax and caspase-3 expression
but suppressed Bcl-2 expression. However, ulinastatin suppressed Bax and caspase-3 expression and promoted Bcl-2 expression. ∗Compared
with IR group (𝑃 < 0.01). #Compared with Sham group (𝑃 < 0.01). Values are the means ± SD, 𝑛 = 8 per group.
oxidative stress by accelerating its scavenging and thus plays
a protective role after spinal cord ischemia reperfusion.
Evaluation of neurologic function is a current means for
accessing the degree of the injury and the outcome of a
medication treatment. The Sham group did not have nerve
function impairment as assessed by using the Basso, Beattie,
and Bresnahan (BBB) hind-limb locomotor rating scale test.
However, in the SCI group the animals became unconscious
at 1 hour time point and their BBB scores increased from
1.41 at 24 h to 4.51 at 72 h [7]. Similarly, in the present study
the Sham group hind-limb function was also normal at the
different time points, but the function in the IR group was
impaired from 12 h to 48 h after reperfusion.
Apoptosis is the process of programmed cell death, which
is indispensable for the normal development and homeostasis
of all multicellular organisms [35]. It was believed that
neuron apoptosis played a pivotal role in the second injury
after spinal cord ischemia reperfusion. Previous research
has demonstrated that a line of genes are involved in the
development of apoptosis, such as the Bcl-2 gene family.
The Bcl-2 gene family consists of 12 different gene products
with pro- and antiapoptotic mechanisms. These pro- and
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Figure 4: Expression level of apoptosis relevant proteins. (a) Western blot identified the expression level of apoptosis relevant proteins: Bax,
Bcl-2, and caspase-3 in the spinal cord after 48 hours of reperfusion. (b) Compared with the Sham group, the IR group showed a significant
increase of Bax, caspase-3 but decrease of Bcl-2. Compared with the IR group, the UTI + IR group demonstrated a significant decreased of
Bax and caspase-3 but increase of Bcl-2. ∗Compared with IR group (𝑃 < 0.01). #Compared with Sham group (𝑃 < 0.01). Values are the
means ± SD, 𝑛 = 8 per group.
antiapoptotic proteins are different with regard to structure
and tissue distribution and exert different functional effects.
Bcl-2 and Bax are essentially involved in the regulation of cell
apoptosis [36]. The antiapoptotic protein Bcl-2 is localized
mainly in the outermitochondrialmembrane. In contrast, the
proapoptotic proteins Bax residemainly in the cytoplasm and
are activated by various apoptotic stimuli. Bax translocates to
the mitochondria, where it forms a complex with Bcl-2. An
increased ratio of Bax/Bcl-2 leads to the formation of pores
in the mitochondria, release of cytochrome c, and activation
of the apoptotic pathway. Bcl-2 can prevent the release of
cytochrome c, along with dATP and Apaf-1, and thus protect
from apoptosis [37]. Chen et al. [38] reported that ulinastatin
reduced the renal dysfunction and injury associated with
ischemia-reperfusion of the kidney by upregulating of Bcl-
2 expression. In our study, the TUNEL staining indicated
that ulinastatin significantly reduced neuronal apoptosis in
spinal cord after spinal cord ischemia reperfusion.Ulinastatin
significantly upregulated Bcl-2 expression while suppressing
the overexpression of Bax, suggesting that ulinastatin has an
antiapoptosis property that plays a protective role attenuating
postischemic spinal cord injury.
Caspases are a family of inactive proenzymes that play a
crucial role in cell apoptosis, which is the scheduled death of
cells. Caspase-3 is a protein that regulates apoptosis by induc-
ing the cleavage of the key cellular proteins and alters cell
integrity [39]. The role of caspase-3 in apoptosis is to activate
the stages of cellular death in a nontraumatic manner. The
intrinsic apoptosis is triggered by a wide range of stimuli that
leads to release of cytochrome c from the mitochondria. This
results in the formation of the apoptosome. The apoptosome
then activates initiator caspase, typically caspase-9, which
leads to the activation of the executioner caspase-3, and
apoptosis finally occurs. Caspase-3 as the executioner is the
common pathway which must be passed through in the
apoptosis cascade, and it is the key one in mammalian cell
apoptosis [40]. Caspase-3 is vital to this process because it
allows the process to progress in sequence, which prevents
undue damage to the remaining cells. In the present study, we
found that the expression of caspase-3 was elevated in the IR
group, but ulinastatin could decrease it significantly; thus the
protective effect of ulinastatinmay be in part due to inhibition
of caspase-3 protein expression.
In summary, our results demonstrate that ulinastatin
improves postischemic neurological function. To be best of
our knowledge, the current study is the first to investigate the
effects and mechanisms of ulinastatin in attenuating spinal
cord ischemia-reperfusion injury. We have shown that uli-
nastatin increases SOD activity and decreases MDA content.
Finally, we have revealed that ulinastatin can inhibit the
neuronal apoptosis by regulating the expression of apoptosis
proteins including Bcl-2, Bax, and caspase-3. Therefore, we
propose that ulinastatin has a protective role and improves
neurological outcome due to its beneficial effects including
antioxidant and antiapoptosis effects. Findings obtained from
the current study may have significant clinical implications
given that ulinastatin is in use clinically.
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Figure 5: TUNEL staining and the apoptotic index of spinal cord neurons. (a) In the UTI + IR group, the number of apoptotic cells was far
less than that in the IR group, which suggested that UTI decreased cell apoptosis caused by IR. (b) In the Sham group, a very few apoptotic
cells were found. (c) In the IR group, the apoptotic cells increased significantly. ∗Compared with IR group (𝑃 < 0.01). #Compared with Sham
group (𝑃 < 0.01). Values are the means ± SD, 𝑛 = 8 per group.
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